Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Scilex Holding Company ( (SCLX) ) has issued an update.
On September 30, 2025, Scilex Holding Company entered into a Warrant Exercise Agreement with existing warrant holders, resulting in the exercise of warrants for 179,236 shares of common stock. The agreement generated approximately $2.7 million in gross proceeds, with $2.5 million allocated to repay outstanding amounts under Tranche B Notes, and the remainder for general corporate purposes. The issuance of new September 2025 Warrants, exercisable immediately and expiring in December 2029, could impact Scilex’s financial structure and market positioning, offering flexibility in future corporate transactions and potential adjustments in exercise prices.
The most recent analyst rating on (SCLX) stock is a Buy with a $770.00 price target. To see the full list of analyst forecasts on Scilex Holding Company stock, see the SCLX Stock Forecast page.
More about Scilex Holding Company
Scilex Holding Company operates in the pharmaceutical industry, focusing on developing and commercializing non-opioid pain management products. The company aims to address the needs of patients and healthcare providers seeking alternatives to traditional opioid treatments.
Average Trading Volume: 244,732
Technical Sentiment Signal: Hold
Current Market Cap: $185.2M
For a thorough assessment of SCLX stock, go to TipRanks’ Stock Analysis page.